Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine risk-reducin...

Descripción completa

Detalles Bibliográficos
Autores principales: Huilgol, Yash S., Keane, Holly, Shieh, Yiwey, Hiatt, Robert A., Tice, Jeffrey A., Madlensky, Lisa, Sabacan, Leah, Fiscalini, Allison Stover, Ziv, Elad, Acerbi, Irene, Che, Mandy, Anton-Culver, Hoda, Borowsky, Alexander D., Hunt, Sharon, Naeim, Arash, Parker, Barbara A., van ‘T Veer, Laura J., Esserman, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333106/
https://www.ncbi.nlm.nih.gov/pubmed/34344894
http://dx.doi.org/10.1038/s41523-021-00306-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333106/
https://www.ncbi.nlm.nih.gov/pubmed/34344894
http://dx.doi.org/10.1038/s41523-021-00306-9

Ejemplares similares